Abstract
Aldehydes are toxic chemicals rapidly metabolized by the enzyme aldehyde dehydrogenase 2 (ALDH2). Nearly 8% of the world population carry an ALDH2 genetic variant rs671 (E504K) causing inefficient aldehyde metabolism recognized by facial flushing after alcohol consumption. Importantly, rs671 carriers have a several-fold increased risk of cancer, neurodegenerative, and heart disease attributed to inefficient aldehyde metabolism. Although rs671 is common, it is unlikely rs671 is the only inactivating ALDH2 mutation in humans.
By recruiting human volunteers reporting facial flushing after alcohol consumption, we identified previously uncharacterized ALDH2 point mutations including rs747096195 (R101G), rs190764869 (R114W), and rs4646777 (G>A). Using ALDH2 recombinant enzyme, we determined R101G and R114W have a reduced efficiency in acetaldehyde metabolism unique to E504K (Vmax/Km, 1.95±0.01+ and 2.77±0.02+ relative to 0.93±0.03, respectively n=3/group, +P<0.001 relative to 7.97±0.51 for wild type ALDH2).
When subjecting human volunteers to an alcohol challenge (0.25g/kg), acetaldehyde levels increased 9-fold for rs671 (E504K), 2-fold for rs747096195 (R101G) and rs190764869 (R114W) and was no different for rs4646777 (G>A) relative to volunteers carrying wild type ALDH2. Further, for volunteers tested, heart rate changes after alcohol strongly correlated with decreased acetaldehyde metabolism (r=0.90, n=26) as opposed to facial flushing. Taken together, we identified novel inactivating ALDH2 point mutations and developed a non-invasive diagnostic test to phenotype aldehyde metabolism in humans. Identifying ALDH2 genetic differences and their phenotype in response to alcohol can provide more precise individual recommendations regarding the health risks of aldehyde exposure.
Competing Interest Statement
Eric Gross holds a patent related to the ALDH2 activator Alda-1 and research funding from the National Institutes of Health. Daria Mochly-Rosen and Che-Hong Chen hold patents related to Alda-1. Dr. Angst is a consultant for Syneos Health, Hassard and Bonnington LLP, and has funding for a research study from Alkahest Inc. Additional authors have no disclosures.
Clinical Trial
Prior to recruitment and testing, IRB approval was obtained from Stanford University (IRB 46095). During IRB review, this study was identified as a basic experimental study involving humans with the manipulation or task used (consuming alcohol) expressly used for measurement and was not considered an intervention. As such, this was not considered a clinical trial.
Funding Statement
Funding for this project was supported by Stanford Chem-H (ERG and DMR), NIAAA AA011147 (DMR), and NIGMS GM119522 (ERG).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB approval was obtained from Stanford University under IRB 46095.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data Availability
All data is presented within the manuscript and is freely available.
